OR WAIT null SECS
October 22, 2021
Ferrer and Treeway, have entered into a license agreement for the development and commercialization of an oral formulation of edaravone (TW001/FNP122).
EMA has recommended the marketing authorization of Trodelvy (sacitusumab govitecan) to treat patients with an aggressive form of breast cancer.
EMA's CHMP has approved two new manufacturing sites and a ready-to-use formulation of Comirnaty.
EMA has started its evaluation of further expanded use of Comirnaty in children aged between five years and 11 years old.
UK government has secured two new antiviral treatments for COVID-19, which may be rolled out in a national clinical study before the end of 2021.
October 21, 2021
In addition to allowing booster shots of the Moderna and J&J vaccines, FDA approved heterologous booster shots.
FDA is expanding its Emerging Technology Program and providing more support for new drug applications that present advanced manufacturing technologies.
The silver-medal ranking is given to companies who demonstrate sustainability practices that place them in the top 20% of companies rated by EcoVadis.
The $19 million contract will expand production capacity of Aptar’s Activ-Film technology, which is used in COVID-19 testing kits.
Boehringer Ingelheim’s Cyltezo (adalimumab-adbm) is the first FDA approved interchangeable biosimilar for Humira.